MA-STILLA/PROMEGA
6.4.2022 15:09:05 CEST | Business Wire | Press release
Stilla Technologies , the multiplex digital PCR company, and Promega Corporation today announced a co-marketing agreement that combines sample preparation with the latest Maxwell® systems and digital PCR on the six-color naica® system . With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. Representative data of the liquid biopsy workflow will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 10, 2022.
“The strategic partnership with Promega enhances our value proposition by bringing a fully-validated sample-to-answer solution for biomarker testing,” said Philippe Mourère, President and CEO, Stilla Technologies. “Promega has demonstrated exceptional quality of results from samples processed with their proven reagents on Maxwell systems, which have been adopted globally for liquid biopsies. I am truly excited about the combined reach and strength that we can bring to the market through a strategic partnership.”
The 6-color naica® platform is being quickly adopted, with end-users developing high multiplex dPCR assays that have been previously unattainable. This adds to the growing body of evidence for the need to study more molecular targets per sample to provide actionable insights.
“In liquid biopsy clinical research, we see a desire to conduct more near-patient testing with faster time to results, lower costs, higher sensitivity, and a highly standardized process from sample preparation to results,” said Tom Livelli, VP, Life Sciences Products & Services, Promega Corporation. “This new end-to-end solution, pairing the Maxwell system with the naica® system, will facilitate the move of highly multiplex genomic signatures from liquid biopsies, typically performed through NGS in centralized labs, to decentralized testing.”
At the AACR Annual Meeting 2022, the companies will present data demonstrating ultrasensitive 32-plex detection from liquid biopsy samples of EGFR mutations in non-small cell lung cancer, in addition to PIK3CA mutations and HER2 amplification in breast cancer. These data will be presented during the following session on April 10, 2022, 1:30 PM – 5:00 PM:
- Poster #527 / 2 – A streamlined workflow for liquid biopsy extraction and highplex digital PCR analysis using the Maxwell® system and 6-color Crystal Digital PCR™
The Stilla and Promega teams will also showcase their combined solution to the scientific community at booths #1807 (Stilla) and #730 (Promega) throughout the AACR Annual Meeting from April 10-13, 2022, in New Orleans. Further data will be released covering a broader range of application areas over the coming months.
About Stilla Technologies
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking Crystal Digital PCR™ solution, the naica® system , is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China and throughout EMEA. To learn more, visit www.stillatechnologies.com and connect with Stilla on Twitter , LinkedIn and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005421/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom